Cargando…

A Randomized, Double‐Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease

BACKGROUND: Agents targeting the metabotropic glutamate receptor 4 have emerged as a potentially attractive new class of drugs for the treatment of Parkinson's disease (PD). OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of foliglurax in reducing off time and dys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rascol, Olivier, Medori, Rossella, Baayen, Corine, Such, Pedro, Meulien, Didier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Regular Issue Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303267/ https://www.ncbi.nlm.nih.gov/pubmed/35218231 http://dx.doi.org/10.1002/mds.28970

Ejemplares similares

A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy
por: Meissner, Wassilios G., et al.
Publicado: (2020)

Double‐Blind, Randomized, Placebo‐Controlled Trial of DA‐9701 in Parkinson's Disease: PASS‐GI Study
por: Choi, Ji‐Hyun, et al.
Publicado: (2020)

Nalmefene in alcohol‐dependent patients with a high drinking risk: Randomized controlled trial
por: Miyata, Hisatsugu, et al.
Publicado: (2019)

Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease
por: Smit, Johan Willem, et al.
Publicado: (2022)

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study
por: Rancans, Elmars, et al.
Publicado: (2020)

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial
por: Videnovic, Aleksandar, et al.
Publicado: (2021)

Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer
por: Maxwell-Armstrong, C A, et al.
Publicado: (2001)

Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2020)

Long‐term safety and efficacy of nalmefene in Japanese patients with alcohol dependence
por: Higuchi, Susumu, et al.
Publicado: (2020)

Cognitive Behavioral Therapy for Anxiety in Parkinsonʼs Disease: A Randomized Controlled Trial
por: Moonen, Anja J.H., et al.
Publicado: (2021)

Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial
por: Sommer, Iris E, et al.
Publicado: (2021)

A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease
por: Hattori, Nobutaka, et al.
Publicado: (2020)

Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial
por: Freire‐Alvarez, Eric, et al.
Publicado: (2021)

Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
por: Brown, David, et al.
Publicado: (2019)

Safety and immunogenicity of a single dose, live-attenuated ‘tetravalent dengue vaccine’ in healthy Indian adults; a randomized, double-blind, placebo controlled phase I/II trial
por: Mohanty, Lalitendu, et al.
Publicado: (2022)

Low‐fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial
por: Phillips, Matthew C.L., et al.
Publicado: (2018)

Evaluation of smartphone‐based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial
por: Lipsmeier, Florian, et al.
Publicado: (2018)

Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy‐Parkinsonism From Parkinson's Disease
por: Quattrone, Andrea, et al.
Publicado: (2022)

Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer
por: Langman, M J S, et al.
Publicado: (1999)

The availability of neither D2 nor CP43 limits the biogenesis of photosystem II in tobacco
por: Fu, Han-Yi, et al.
Publicado: (2020)

Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics
por: Bandres‐Ciga, Sara
Publicado: (2022)

Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms
por: Xie, Aoji, et al.
Publicado: (2022)

The Parkinson's Disease DNA Variant Browser
por: Kim, Jonggeol J., et al.
Publicado: (2021)

Diabetes and Neuroaxonal Damage in Parkinson's Disease
por: Vijiaratnam, Nirosen, et al.
Publicado: (2022)

The Myelin‐Weighted Connectome in Parkinson's Disease
por: Boshkovski, Tommy, et al.
Publicado: (2021)

Towards spruce-type photosystem II: consequences of the loss of light-harvesting proteins LHCB3 and LHCB6 in Arabidopsis
por: Ilíková, Iva, et al.
Publicado: (2021)

A Phase 2 Proof‐of‐Concept, Randomized, Placebo‐Controlled Trial of CX‐8998 in Essential Tremor
por: Papapetropoulos, Spyros, et al.
Publicado: (2021)

Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo‐Controlled Trial
por: Biglan, Kevin, et al.
Publicado: (2021)

Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease
por: Vila, Miquel
Publicado: (2019)

The Impact of Type 2 Diabetes in Parkinson's Disease
por: Athauda, Dilan, et al.
Publicado: (2022)

GP2: The Global Parkinson's Genetics Program
Publicado: (2021)

Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities
por: Mackerras, D, et al.
Publicado: (1999)

Randomized, double‐blind, 6‐week non‐inferiority study of lurasidone and risperidone for the treatment of schizophrenia
por: Feng, Yuan, et al.
Publicado: (2020)

Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study
por: Murata, Miho, et al.
Publicado: (2018)

A Wearable Proprioceptive Stabilizer (Equistasi®) for Rehabilitation of Postural Instability in Parkinson’s Disease: A Phase II Randomized Double-Blind, Double-Dummy, Controlled Study
por: Volpe, Daniele, et al.
Publicado: (2014)

A totally data-driven whole-brain multimodal pipeline for the discrimination of Parkinson's disease, multiple system atrophy and healthy control
por: Nemmi, F., et al.
Publicado: (2019)

Orthostatic Hypotension: A Prodromal Marker of Parkinson's Disease?
por: Dommershuijsen, Lisanne J., et al.
Publicado: (2020)

Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review
por: Carey, Guillaume, et al.
Publicado: (2020)

Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource
por: Iwaki, Hirotaka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5go9cjrcf4gi5jfuespphbf9u9